June 1, 2009
LOS ANGELES, June 1, 2009 – KYTHERA Biopharmaceuticals, Inc. ("Kythera") announced today its participation in the private company forum at the 30th Annual Goldman Sachs Global Healthcare Conference on Monday, June 8, 2009 from 3:30 to 5:30 p.m. Eastern Time. This event marks KYTHERA’s third appearance at the Goldman Sachs Private Company Forum. The Company previously participated in 2007 and 2008.
“We are very excited to be participating at the Goldman Sachs Global Healthcare Conference for a third year,” said Keith Leonard, President and CEO. “The conference allows us to build relationships with high-quality private investors with a goal of further progressing our lead product candidate, ATX-101, an adipolytic agent for the reduction of localized fat deposits.”
KYTHERA announced in January positive results from two Phase 2 studies with ATX-101. The two Phase 2, randomized, double-blind, placebo-controlled, dose-ranging studies enrolled a total of 157 patients and were conducted across 10 centers in the United Kingdom, Canada and Australia. In both studies, ATX-101 was safe and tolerable and demonstrated statistically significant efficacy versus placebo.
Keith Leonard, President and Chief Executive Officer, Amit Munshi, Chief Business Officer and John Smither, Chief Financial Officer, will be available to discuss the Company during the forum. The conference will be held June 8-11, 2009 at the Grant Hyatt Hotel in New York City.